Predictor of subsequent target lesion revascularization in patients with drug-eluting stent restenosis undergoing percutaneous coronary intervention

Journal of Cardiology

Volumn 55, Issue 3, 2010, Pages 391-396

  Takasawa, Yosuke ^a,b   Iijima, Raisuke ^a   Shiba, Masanori ^c   Nakamura, Masato ^a   Sugi, Kaoru ^a  

^a TOHO UNIVERSITY   (Japan)

^b Toshiba Hospital   (Japan)

^c TOHO UNIVERSITY   (Japan)

Author keywords

Drug eluting stent; In stent restenosis; Percutaneous coronary intervention

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; HEPARIN; PACLITAXEL; RAPAMYCIN; TICLOPIDINE;

AGED; ANGIOCARDIOGRAPHY; ANGIOGRAPHY; ARTICLE; BARE METAL STENT; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DRUG ELUTING STENT; EXERCISE TEST; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PREDICTION; PRESCRIPTION; RESTENOSIS; REVASCULARIZATION;

AGED; ANGIOPLASTY, BALLOON; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CORONARY ANGIOGRAPHY; CORONARY RESTENOSIS; DIABETES COMPLICATIONS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; PACLITAXEL; SIROLIMUS; STENTS;

EID: 77952104567     PISSN: 09145087     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jjcc.2010.01.003     Document Type: Article

References (23)

1. Komatsu R., Ueda M., Naruko T., Kojima A., and Becker A.E. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 98 (1998) 224-233
2. Eltchaninoff H., Koning R., Tron C., Gupta V., and Cribier A. Balloon angioplasty for the treatment of coronary in-stent restenosis: immediate results and 6-month angiographic recurrent restenosis rate. J Am Coll Cardiol 32 (1998) 980-984
3. vom Dahl J., Dietz U., Haager P.K., Silber S., Niccoli L., Buettner H.J., Schiele F., Thomas M., Commeau P., Ramsdale D.R., Garcia E., Hamm C.W., Hoffmann R., Reineke T., and Klues H.G. Rotational atherectomy does not reduce recurrent in-stent restenosis: results of the angioplasty versus rotational atherectomy for treatment of diffuse in-stent restenosis trial (ARTIST). Circulation 105 (2002) 583-588
4. Iijima R., Ikari Y., Anzai H., Nishida T., Tsunoda T., Nakamura M., Hara K., and Yamaguchi T. The impact of cutting balloon angioplasty for the treatment of diffuse in-stent restenosis. J Invasive Cardiol 15 (2003) 427-431
5. Stone G.W., Ellis S.G., O'Shaughnessy C.D., Martin S.L., Satler L., McGarry T., Turco M.A., Kereiakes D.J., Kelley L., Popma J.J., Russell M.E., and TAXUS V ISR Investigators. Paclitaxel-eluting stents vs vascular brachytherapy for in-stent restenosis within bare-metal stents: the TAXUS V ISR randomized trial. JAMA 295 (2006) 1253-1263
6. Kastrati A., Mehilli J., von Beckerath N., Dibra A., Hausleiter J., Pache J., Schühlen H., Schmitt C., Dirschinger J., Schömig A., and ISAR-DESIRE Study Investigators. Sirolimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis: a randomized controlled trial. JAMA 293 (2005) 165-171
7. Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., Holmes D.R., O'Shaughnessy C., Caputo R.P., Kereiakes D.J., Williams D.O., Teirstein P.S., Jaeger J.L., Kuntz R.E., and SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349 (2003) 1315-1323
8. Mehilli J., Dibra A., Kastrati A., Pache J., Dirschinger J., and Schömig A. Randomized trial of paclitaxel- and sirolimus-eluting stents in small coronary vessels. Eur Heart J 27 (2006) 260-266
9. Qasim A., Cosgrave J., Latib A., and Colombo A. Long-term follow-up of drug-eluting stents when inserted for on- and off-label indications. Am J Cardiol 100 (2007) 1619-1624
10. Cosgrave J., Melzi G., Corbett S., Biondi-Zoccai G.G., Babic R., Airoldi F., Chieffo A., Sangiorgi G.M., Montorfano M., Michev I., Carlino M., and Colombo A. Repeated drug-eluting stent implantation for drug-eluting stent restenosis: the same or a different stent. Am Heart J 153 (2007) 354-359
11. Kitahara H., Kobayashi Y., Takebayashi H., Fujimoto Y., Nakamura Y., Kuroda N., Himi T., Miyazaki A., Haruta S., and Komuro I. Re-restenosis and target lesion revascularization after treatment of sirolimus-eluting stent restenosis: retrospective analysis of 4 Japanese hospitals. Circ J 73 (2009) 867-871
12. Mehran R., Dangas G., Abizaid A.S., Mintz G.S., Lansky A.J., Satler L.F., Pichard A.D., Kent K.M., Stone G.W., and Leon M.B. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation 100 (1999) 1872-1878
13. Nobuyoshi M., and Yokoi H. How to manage in-stent restenosis. Catheter Cardiovasc Interv 49 (2000) 30-31
14. Colombo A., Orlic D., Stankovic G., Corvaja N., Spanos V., Montorfano M., Liistro F., Carlino M., Airoldi F., Chieffo A., and Di Mario C. Preliminary observations regarding angiographic pattern of restenosis after rapamycin-eluting stent implantation. Circulation 107 (2003) 2178-2180
15. Virmani R., Guagliumi G., Farb A., Musumeci G., Grieco N., Motta T., Mihalcsik L., Tespili M., Valsecchi O., and Kolodgie F.D. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious?. Circulation 109 (2004) 701-705
16. Aoki J., Nakazawa G., Tanabe K., Hoye A., Yamamoto H., Nakayama T., Onuma Y., Higashikuni Y., Otsuki S., Yagishita A., Yachi S., Nakajima H., and Hara K. Incidence and clinical impact of coronary stent fracture after sirolimus-eluting stent implantation. Catheter Cardiovasc Interv 69 (2007) 380-386
17. Smith Jr. S.C., Faxon D., Cascio W., Schaff H., Gardner T., Jacobs A., Nissen S., and Stouffer R. Prevention conference VI: diabetes and cardiovascular disease: writing group VI: revascularization in diabetic patients. Circulation 105 (2002) 165-169
18. Iijima R., Ndrepepa G., Mehilli J., Markwardt C., Bruskina O., Pache J., Ibrahim M., Schömig A., and Kastrati A. Impact of diabetes mellitus on long-term outcomes in the drug-eluting stent era. Am Heart J 154 (2007) 688-693
19. Kastrati A., Dibra A., Mehilli J., Mayer S., Pinieck S., Pache J., Dirschinger J., and Schömig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 113 (2006) 2293-2300
20. Byrne R.A., Iijima R., Mehilli J., Pinieck S., Bruskina O., Schömig A., and Kastrati A. Durability of antirestenotic efficacy in drug-eluting stents with and without permanent polymer. JACC Cardiovasc Interv 2 (2009) 291-299
21. Byrne R., Iijima R., Mehilli J., Pache J., Schulz S., Schömig A., and Kastrati A. Treatment of paclitaxel-eluting stent restenosis with sirolimus-eluting stent implantation: angiographic and clinical outcomes. Rev Esp Cardiol 61 (2008) 1134-1139
22. Finn A.V., Kolodgie F.D., Harnek J., Guerrero L.J., Acampado E., Tefera K., Skorija K., Weber D.K., Gold H.K., and Virmani R. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus- or paclitaxel-eluting stents. Circulation 112 (2005) 270-278
23. Unverdorben M., Vallbracht C., Cremers B., Heuer H., Hengstenberg C., Maikowski C., Werner G.S., Antoni D., Kleber F.X., Bocksch W., Leschke M., Ackermann H., Boxberger M., Speck U., Degenhardt R., et al. Paclitaxel-coated balloon catheter versus paclitaxel-coated stent for the treatment of coronary in-stent restenosis. Circulation 119 (2009) 2986-2994